Eszopiclone: what did the insomnia trial show?
788 adults aged 21–69 with primary insomnia were randomized to eszopiclone 3 mg (593 participants) or placebo (195) nightly for six months.
Patient reports of sleep onset, overnight wakefulness, sleep duration and quality improved versus placebo throughout follow-up. Daytime function ratings also improved. Unpleasant taste and headache were the most common adverse events.
Outcomes were reported through a voice-response system. No tolerance signal in this trial does not establish freedom from dependence or rare harms. Separate FDA warnings address serious complex sleep behaviors.
These results apply to the studied population, formulation and follow-up.
What might this mean, and what would change the interpretation?
This is a selected trial summary, not a full literature review or formal quality appraisal.
What would clarify this: Further studies of long-term outcomes and different patient groups.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.